Qingdao Vland Biotech Past Earnings Performance
Past criteria checks 3/6
Qingdao Vland Biotech's earnings have been declining at an average annual rate of -2.5%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 8.9% per year. Qingdao Vland Biotech's return on equity is 5.8%, and it has net margins of 6.6%.
Key information
-2.5%
Earnings growth rate
-8.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 8.9% |
| Return on equity | 5.8% |
| Net Margin | 6.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Qingdao Vland Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,253 | 83 | 340 | 115 |
| 31 Dec 23 | 1,199 | 81 | 327 | 111 |
| 30 Sep 23 | 1,213 | 71 | 324 | 111 |
| 30 Jun 23 | 1,175 | 64 | 321 | 104 |
| 31 Mar 23 | 1,140 | 62 | 308 | 101 |
| 31 Dec 22 | 1,163 | 70 | 309 | 102 |
| 30 Sep 22 | 1,148 | 92 | 300 | 99 |
| 30 Jun 22 | 1,134 | 109 | 288 | 104 |
| 31 Mar 22 | 1,141 | 122 | 292 | 103 |
| 31 Dec 21 | 1,151 | 133 | 291 | 101 |
| 30 Sep 21 | 1,100 | 130 | 275 | 96 |
| 30 Jun 21 | 1,078 | 126 | 281 | 91 |
| 31 Mar 21 | 1,030 | 116 | 276 | 86 |
| 31 Dec 20 | 960 | 109 | 264 | 80 |
| 30 Sep 20 | 922 | 103 | 282 | 74 |
| 30 Jun 20 | 884 | 89 | 278 | 75 |
| 31 Mar 20 | 870 | 89 | 272 | 74 |
| 31 Dec 19 | 847 | 78 | 269 | 75 |
| 30 Sep 19 | 840 | 79 | 253 | 78 |
| 30 Jun 19 | 824 | 81 | 235 | 73 |
| 31 Mar 19 | 808 | 84 | 229 | 70 |
| 31 Dec 18 | 814 | 83 | 227 | 70 |
| 30 Sep 18 | 805 | 86 | 396 | 121 |
| 31 Dec 17 | 799 | 86 | 233 | 71 |
| 31 Dec 16 | 781 | 83 | 240 | 77 |
| 31 Dec 15 | 752 | 70 | 227 | 83 |
| 31 Dec 14 | 728 | 53 | 336 | 0 |
Quality Earnings: 603739 has a large one-off gain of CN¥28.2M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 603739's current net profit margins (6.6%) are higher than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603739's earnings have declined by 2.5% per year over the past 5 years.
Accelerating Growth: 603739's earnings growth over the past year (33%) exceeds its 5-year average (-2.5% per year).
Earnings vs Industry: 603739 earnings growth over the past year (33%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 603739's Return on Equity (5.8%) is considered low.